>>Signaling Pathways>> Others>> Nucleic Acid Turnover/Signaling>>MST-312

MST-312 (Synonyms: Telomerase Inhibitor IX)

Catalog No.GC18769

DB2115(tertahydrochloride)는 골수 마스터 레귤레이터 PU.1의 강력한 억제제입니다. DB2115(tertahydrochloride)는 백혈병과 같은 혈액암 및 PU와 관련된 기타 상태를 포함한 암을 연구할 가능성이 있습니다. 1 기능장애(특허 WO2017223260A1, 화합물 DB2115에서 추출) .

Products are for research use only. Not for human use. We do not sell to patients.

MST-312 Chemical Structure

Cas No.: 368449-04-1

Size 가격 재고 수량
5mg
US$71.00
재고 있음
10mg
US$123.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
MST312 is a telomerase inhibitor (IC50 = 0.67 μM in a TRAP assay). It is selective for telomerase over DNA polymerase when used at concentrations up to 3 μM. MST312 inhibits growth of U937 cells via telomere shortening (GI50 = 1.7 μM). It reduces cell number and expression of the proliferation marker MIB-1 as well as increases DNA damage in primary pediatric ependymoma tumor cells. MST312 decreases survival of H460 and H1299 non-small cell lung cancer (NSCLC) cells in a dose-dependent manner with a greater effect on the aldehyde dehydrogenase positive (ALDH+) cancer stem cell population. In vivo, MST312 (40 mg/kg) reduces tumor size by 70% in an H460 mouse xenograft model. MST312 also inhibits replication of herpes simplex virus 2 (HSV-2) and a clinical isolate of HSV-1 and decreases accumulation of early and late viral proteins in HEp-2 cells infected with HSV-1.

리뷰

Review for MST-312

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MST-312

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.